Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
In its April 2019 NEWSletter, the Patented Medicine Prices Review Board (PMPRB) announced that the Steering Committee on Guidelines Modernization would hold its final meeting on May 13, 2019, to discuss both a draft report of its deliberations and the Working Group's final report
In its April 2019 NEWSletter, the Patented Medicine
Prices Review Board (PMPRB) announced that the Steering Committee
on Guidelines Modernization would hold its final meeting on May 13,
2019, to discuss both a draft report of its deliberations and the
Working Group's final report (released March 6, 2019). Once the
Steering Committee's report has been finalized and the
regulatory amendments have been published in Part II of the
Canada Gazette (
expected this spring), the PMPRB will release its draft
Guidelines for public consultation.
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.